MT Newswires
Lexicon Says FDA Raised No Objections to Advancing Pilavapadin Into Phase 3 Development During Meeting
➖
AI Sentiment
Neutral
5/10
Lexicon Pharmaceuticals Inc. News
Latest updates and market news for LXRX
2 news
Jan 17 - Jan 23, 2026
Page 1
GlobeNewswire
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
📈
AI Sentiment
Highly Positive
9/10
Share this news page